TrialPath
Recruiting

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477 · University of California, Davis
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Participants will be randomized to an intervention arm or a standard of care (SOC) arm. Participants in the intervention arm will undergo pretreatment assessment with PROphet Clinical Benefit (CB) and the Cancer and Aging Research Group Toxicity Tool (CARG-TT); data from the assessments will be used to select systemic therapy, which can be any SOC treatment that incorporates a Programmed death-ligand 1 (PD-(L)1) antibody with or without chemotherapy and/or with or without Cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody. Participants in the SOC arm will undergo SOC biomarker assessment and subsequent selection of SOC systemic therapy. The primary endpoint is 12-month progression free survival (PFS). The findings will be stratified according to participant performance status and tumor PD-L1 score. The hypothesis is that risk-adapted, proteomic-guided systemic therapy will improve PFS among patients with previously untreated advanced NSCLC compared to SOC systemic therapy.
Eligibility criteria
Inclusion Criteria: * Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to receive standard of care immune checkpoint inhibitor-based therapy given with palliative intent. * Age ≥18 years at the time of consent. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥50%). * Ability to understand and willingness to sign the informed consent form (ICF). * Stated ability and willingness to adhere to all protocol requirements while on study Exclusion Criteria: * Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1. * Medical comorbidities precluding immune checkpoint inhibitor-based therapy per treating investgator's discretion. * Previous systemic therapy for metastatic Stage IIIC or IV NSCLC. Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion. * Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on study
Study design
Enrollment target: 56 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-01-30
Estimated completion: 2036-12
Last updated: 2026-08-25
Interventions
Drug: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.Drug: Standard of Care
Primary outcomes
  • • The primary objective is to evaluate 12-month progression free survival (PFS) of systemic therapy informed by PROphet CB and CARG-TT (intervention arm) versus standard of care systemic therapy (Up to 12 months.)
Sponsor
University of California, Davis · other
With: National Cancer Institute (NCI)
Contacts & investigators
ContactOffice of Clinical Research · contact · OCRReferral@health.ucdavis.edu · (916) 734-3772
InvestigatorSurbhi Singhal, MD · principal_investigator, University of California, Davis
All locations (4)
Enloe Health Regional Cancer CenterRecruiting
Chico, California, United States
Rideout Cancer CenterRecruiting
Marysville, California, United States
University of California Davis Comprehensive Cancer CenterRecruiting
Sacramento, California, United States
Tahoe Forest Cancer CenterRecruiting
Truckee, California, United States